Potential role of N-methyl-D-aspartate receptors as executors of
... Wilcock et al., 2002; Reisberg et al., 2003; Tariot et al., 2004; Gauthier et al., 2005; Reisberg et al., 2006). In general, published and unpublished data indicate that at therapeutic doses (typically 20–30 mg/day), at steadystate (chronic treatment for several weeks), plasma levels of memantine ar ...
... Wilcock et al., 2002; Reisberg et al., 2003; Tariot et al., 2004; Gauthier et al., 2005; Reisberg et al., 2006). In general, published and unpublished data indicate that at therapeutic doses (typically 20–30 mg/day), at steadystate (chronic treatment for several weeks), plasma levels of memantine ar ...
Volume 50 Number 1
... Pharmacia-ASPET Award Jerry J. Buccafusco, Ph.D., Director of the Alzheimer’s Research Center, Professor of Pharmacology at the Medical College of Georgia, and Director of the Neuropharmacology Laboratory at the Charlie Norwood Veterans Administration Medical Center in Augusta, Georgia, is the recip ...
... Pharmacia-ASPET Award Jerry J. Buccafusco, Ph.D., Director of the Alzheimer’s Research Center, Professor of Pharmacology at the Medical College of Georgia, and Director of the Neuropharmacology Laboratory at the Charlie Norwood Veterans Administration Medical Center in Augusta, Georgia, is the recip ...
министерство здравоохранения республики беларусь
... 9. The answer is В (Atenolol): Drugs which are lipid in-soluble, do not cross blood brain barrier. Three β-blockers are lipid insoluble: Atenolol; Nadolol; Sotalol. All of these three share certain common characteristics which are frequently asked: — do not cross blood brain barrier and theref ...
... 9. The answer is В (Atenolol): Drugs which are lipid in-soluble, do not cross blood brain barrier. Three β-blockers are lipid insoluble: Atenolol; Nadolol; Sotalol. All of these three share certain common characteristics which are frequently asked: — do not cross blood brain barrier and theref ...
100 Essential Drugs - University of Toledo
... MOA: accelerates antithrombin III binding to thrombin and antithrombin III, inactivates thrombin, as well as factors IXa, Xa, XIa, XIIa, and kallikrein; inhibits clot formation, but does not dissolve existing clots (only drug that produces anticoagulation within minutes) I: used in pts. at high risk ...
... MOA: accelerates antithrombin III binding to thrombin and antithrombin III, inactivates thrombin, as well as factors IXa, Xa, XIa, XIIa, and kallikrein; inhibits clot formation, but does not dissolve existing clots (only drug that produces anticoagulation within minutes) I: used in pts. at high risk ...
Prodrugs for Amines
... membrane penetration by passive diffusion. The impact of this is amplified for the large number of amino drugs that are required to penetrate the blood brain barrier in order to reach their pharmacological targets. A second issue that can affect the development of amino drugs is instability. An exam ...
... membrane penetration by passive diffusion. The impact of this is amplified for the large number of amino drugs that are required to penetrate the blood brain barrier in order to reach their pharmacological targets. A second issue that can affect the development of amino drugs is instability. An exam ...
Chemotherapy-Induced Nausea and Vomiting
... the amygdala. Evidence for this pathway is less well established than for other proposed sites of chemotherapeutic action. ...
... the amygdala. Evidence for this pathway is less well established than for other proposed sites of chemotherapeutic action. ...
